Due to significant intra-tumor heterogeneity [3], these surgical samples also reflect poorly the entire molecular landscape of the tumor, potentially missing detection of currently established prognostic markers (e.g., IDH mutation and MGMT promoter hypermethylation) [4–6] and limiting our ability to identify other viable targetable mutations. This evidence concerns the gene IDH1 and neoplasm.